Currently, there are 30.88M common shares owned by the public and among those 22.95M shares have been available to trade.
The company’s stock has a 5-day price change of -2.51% and 1.19% over the past three months. VINC shares are trading -40.85% year to date (YTD), with the 12-month market performance down to -29.33% lower. It has a 12-month low price of $0.51 and touched a high of $9.37 over the same period. VINC has an average intraday trading volume of 164.50K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.44%, 1.58%, and -57.12% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Vincerx Pharma Inc (NASDAQ: VINC) shares accounts for 34.66% of the company’s 30.88M shares outstanding.
It has a market capitalization of $21.55M and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$1.31. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.72% over the week and 7.44% over the month.
Earnings per share for the fiscal year are expected to increase by 55.73%, and 10.76% over the next financial year.
Looking at the support for the VINC, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on January 14, 2022, with the firm’s price target at $25. Cantor Fitzgerald coverage for the Vincerx Pharma Inc (VINC) stock in a research note released on December 23, 2021 offered a Overweight rating with a price target of $25. SVB Leerink was of a view on November 01, 2021 that the stock is Outperform, while Laidlaw gave the stock Buy rating on September 13, 2021, issuing a price target of $30. B. Riley Securities on their part issued Buy rating on August 25, 2021.
